Moderna (MRNA) News Today

Moderna, Inc. (NASDAQ: MRNA) has continued to benefit from strong investor interest in its oncology pipeline and broader mRNA platform. The stock has surged roughly 566% over the past year, increasing attention on both potential growth catalysts and valuation risks.

• Positive Sentiment: Moderna’s addition to the Nasdaq-100 could create incremental demand from index-tracking funds and improve the stock’s visibility with institutional investors. The inclusion follows the company’s sharp rally and improved prospects for cancer therapies. Moderna’s Nasdaq-100 Entry
• Positive Sentiment: Tempus announced an expanded, multiyear collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized cancer vaccine being tested with Keytruda in melanoma and other cancers. The agreement reinforces the potential for Moderna to build a commercial oncology franchise beyond COVID-19, although the therapy remains dependent on clinical and regulatory success. Tempus Collaboration Announcement
• Positive Sentiment: Reports highlighting Moderna’s manufacturing capabilities and efforts to apply its COVID-era production lessons to personalized cancer vaccines support the view that the company is preparing to scale an oncology business. An experimental AI-based approach that could reduce cold-storage requirements for mRNA vaccines may also improve logistics and distribution over time. Moderna Manufacturing Update
• Neutral Sentiment: Morgan Stanley raised its price target from $89 to $95 but maintained an Equal Weight/Hold rating. The target remains substantially below the recent trading level, signaling that the analyst views the stock’s rally as having outpaced near-term fundamental value. Morgan Stanley Hold Rating
• Neutral Sentiment: Moderna was among the healthcare stocks leading a stronger sector performance, providing additional market momentum, though this factor is broader-market driven rather than company-specific. Healthcare Stocks Market Update